Deals this week: ReShape Lifesciences, CALCIVIS

10 August 2018 (Last Updated November 22nd, 2018 11:23)

ReShape Lifesciences Inc has raised $0.6m through the private placement of shares of its common stock priced at $0.6 each.

ReShape Lifesciences Inc has raised $0.6m through the private placement of shares of its common stock priced at $0.6 each.

Investors will also receive unregistered warrants to purchase one million shares of the company’s common stock priced at $1.1 a share.

Based in the US, ReShape Lifesciences is a manufacturer of medical devices used for the treatment of obesity and metabolic diseases.

The company plans to use the proceeds towards clinical development, working capital, and other general corporate purposes.

Fox Rothschild LLP has been appointed as the legal advisor to the company for the offering.

CALCIVIS has raised £3.15m ($4.13m) through a venture financing round led by existing investors Archangel Investors, Julz, and the Scottish Investment Bank.

The company plans to use the funds to support the regulatory process for its CALCIVIS Imaging System in the US and to support its commercialisation in the UK.

CALCIVIS imaging system is designed for the assessment of active dental demineralisation.

Based in the UK, CALCIVIS is a provider of innovative medical devices for dental clinicians.

“The company plans to use the funds towards the development of Nash Pharma’s business division.”

Tandem Diabetes Care Inc has raised $100m through an underwritten public offering of 3.5 million shares of its common stock priced at $28.50 a share.

The underwriters will be granted an option to purchase an additional 0.52 million shares within 30 days of the offer closure.

Based in the US, Tandem Diabetes is a developer of medical devices used for the treatment of diabetes.

The proceeds from the offering are intended to be used towards working capital, general corporate purposes, and to clear the debts owed to the investor, Capital Royalty Partners.

Stradling Yocca Carlson & Rauth PC has been appointed as the legal advisor to the company for the offering.

Bonesupport AB and MTF Biologics have signed an agreement to expand and strengthen the former’s bone graft material product offerings in the US.

The agreement will provide Bonesupport with the rights to two forms of bone graft materials that are completely made from demineralised bone matrix.

The products distributed by MTF Biologics will be launched under the Bonesupport brand.

Based in Sweden, Bonesupport is a subsidiary of Bonesupport Holding and a developer of injectable osteo-conductive and drug-eluting bioceramic products, while MTF Biologics is a non-profit organisation based in the US.

Breathtec BioMedical Inc has raised C$1m ($0.76m) through the private placement of shares.

Breathtec has simultaneously signed an agreement to purchase all the outstanding shares of the Canada-based clinical-stage pharmaceutical company, Nash Pharmaceuticals Inc.

Also based in Canada, Breathtec is a developer of medical devices for the early screening of life-threatening diseases.

The company plans to use the funds towards the development of Nash Pharma’s business division.